Biopharmaceutical News and Research

RSS

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

NeoStem revenues increase 13% for the year ended December 31, 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, is today providing unaudited results for 2010 and an update of recent activities.

2 Apr 2011

ACADIA extends collaboration agreement with Allergan for drug discovery platform

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc.

1 Apr 2011

Pfizer reports details of financial interactions with the medical and scientific community

Pfizer Inc. today released a report detailing the company's financial interactions with health care professionals and researchers in 2010.

1 Apr 2011

Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported the outcome from its Phase 3 program evaluating OMS103HP in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery.

1 Apr 2011

FDA grants Nile Fast Track designation for cenderitide post-acute development program

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Nile's post-acute development program for cenderitide, which has the goal of reducing cardiovascular mortality and cardiovascular re-hospitalization in the post-acute period in patients with acute decompensated heart failure.

31 Mar 2011

Sinovac reports fourth quarter net sales of $9.1 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended December 31, 2010.

31 Mar 2011

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

31 Mar 2011

Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of small biologic therapies called Engineered Toxin Bodies, announced today that it will present preclinical data in two poster presentations at the 102nd American Association for Cancer Research annual meeting in Orlando, FL during April 2-6, 2011.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Gilead and Yale enter multi-year cancer research collaboration

Gilead Sciences, Inc. and Yale School of Medicine today announced the formation of a multi-year research collaboration focused on the discovery of novel cancer therapies. The research effort will initially span four years with an option to renew for up to ten years.

30 Mar 2011

Researchers develop new drug for multiple cancer treatment

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.

30 Mar 2011

Cephalon intends to make takeover bid for ChemGenex

Cephalon, Inc. and ChemGenex Pharmaceuticals Limited today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex.

29 Mar 2011

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.

29 Mar 2011

Anergis SA closes funding round for allergy vaccines

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

28 Mar 2011

Almac extends Pharma Services business unit to increase demand for storage capacity

In response to increased client demand for cold and dedicated frozen storage capacity for biopharmaceuticals, Almac's Pharma Services business unit has expanded its commercial facilities to include an additional 6124 sq ft of cold and frozen storage.

25 Mar 2011

Boehringer Ingelheim formally acquires Amgen's Fremont manufacturing site

Today Boehringer Ingelheim formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, California. This acquisition involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site.

25 Mar 2011

Perceptive Informatics announces eClinical Product Suite survey results

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced results of a survey conducted during its recent webinar entitled "Designing and Delivering an eClinical Product Suite."

From Parexel 24 Mar 2011

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics.

24 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Biopharmaceutical News and Research

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

NeoStem revenues increase 13% for the year ended December 31, 2010

ACADIA extends collaboration agreement with Allergan for drug discovery platform

Pfizer reports details of financial interactions with the medical and scientific community

Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery

FDA grants Nile Fast Track designation for cenderitide post-acute development program

Sinovac reports fourth quarter net sales of $9.1 million

RXi Pharmaceuticals to acquire Apthera

Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Gilead and Yale enter multi-year cancer research collaboration

Researchers develop new drug for multiple cancer treatment

Cephalon intends to make takeover bid for ChemGenex

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

Anergis SA closes funding round for allergy vaccines

Almac extends Pharma Services business unit to increase demand for storage capacity

Boehringer Ingelheim formally acquires Amgen's Fremont manufacturing site

Perceptive Informatics announces eClinical Product Suite survey results

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

KaloBios commences KB004 Phase 1 trial in patients with leukemia

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News